Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: Data from the French pulmonary hypertension registry-Reference-Cited by-同舟云学术

Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: Data from the French pulmonary hypertension registry

Published:2014-04 Issue:3 Volume:172 Page:561-567
ISSN:0167-5273
Container-title:International Journal of Cardiology
language:en
Short-container-title:International Journal of Cardiology

Author:

Bergot Emmanuel,Sitbon Olivier,Cottin Vincent,Prévot Grégoire,Canuet Matthieu,Bourdin Arnaud,de Groote Pascal^ORCID,Rottat Laurence,Gressin Virginie,Jaïs Xavier,Humbert Marc,Simonneau Gérald

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference30 articles.

1. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry;D'Alonzo;Ann Intern Med,1991

2. Pharmacotherapeutic management of pulmonary arterial hypertension;Anderson;Cardiol Rev,2010

3. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era;Humbert;Circulation,2010

4. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial;Rubin;Ann Intern Med,1990

5. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group;Barst;N Engl J Med,1996

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pulmonary arterial hypertension treatment: an individual participant data network meta-analysis;European Heart Journal;2024-02-28

2. Contribution of pressure and flow changes to resistance reduction after pulmonary arterial hypertension treatment: a meta-analysis of 3898 patients;ERJ Open Research;2023-12-07

3. Tolerability, safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol (Veletri®): a prospective, 6-months, open label, observational, non-interventional study;Respiratory Research;2023-01-18

4. The treatment strategy of connective tissue disease associated pulmonary arterial hypertension: Evolving into the future;Pharmacology & Therapeutics;2022-11

5. Chest pain in a patient with pulmonary arterial hypertension;Revista Portuguesa de Cardiologia;2022-01